1 story in the last 7 days
The latest elijilly news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks elijilly across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
The S&P 500 has gained 23% since Trump's inauguration and its Shiller CAPE ratio remains at historic highs. Inflation and high valuations suggest the bull market may end soon. Eli Lilly, up 1.56%, leads in obesity drugs with Mounjaro and Zepbound, both based on tirzepatide, a GLP-1 drug that targets hormonal digestion pathways.
Summaries by ByteBrief